Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow
James Stevenson(Cleveland Clinic), Peter J. O’Dwyer(University of Pennsylvania), Weijing Sun(University of Kansas Medical Center), David J. Vaughn(University of Pennsylvania), Mitchell D. Schnall(California University of Pennsylvania), Ross Zimmer(Regional Cancer Center), Scott L. Young(Regional Cancer Center), Michael R.L. Stratford(Regional Cancer Center), Maryann Gallagher(Regional Cancer Center), William P. Petros(Regional Cancer Center), Mark Rosen(California University of Pennsylvania), David J. Chaplin(Regional Cancer Center), Bruce J. Giantonio(Northwestern University), Daniel G. Haller(University of Pennsylvania)
Cited by 293
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
|CA A Cancer Journal for Clinicians|2007|2.6k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k